<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767804</url>
  </required_header>
  <id_info>
    <org_study_id>X396-CLI-301</org_study_id>
    <nct_id>NCT02767804</nct_id>
  </id_info>
  <brief_title>eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xcovery Holding Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xcovery Holding Company, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy and safety of X-396
      (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that
      have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with
      ALK-positive NSCLC that have received up to 1 prior chemotherapy regimen and no prior ALK
      tyrosine kinase inhibitor (TKI), to obtain additional pharmacokinetic (PK) data from sparse
      PK sampling, to compare the quality of life (QoL) in patients receiving X-396 vs. crizotinib,
      to evaluate the status of exploratory biomarkers and correlate with clinical outcome, and to
      obtain germline DNA samples for possible pharmacogenetic analysis in the event that outliers
      with respect to efficacy, tolerability/safety, or exposure are identified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by independent radiology review based on RECIST v. 1.1 criteria</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CNS response rate based on independent radiology review</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CNS response rate based on investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to CNS progression</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported time to deterioration (TTD) as measured by EORTC C30/LC13 QoL questionnaire</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported TTD as measured by Lung Cancer Symptom Scale (LCSS)</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported health-related quality of life (HRQoL) as measured by EORTC C30/LC13 QoL questionnaire</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported HRQoL as measured by LCSS</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations (Cmax) at participating sites</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentrations (Cmin) at participating sites</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>X-396 (ensartinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crizotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X-396 (ensartinib)</intervention_name>
    <description>oral ALK inhibitor</description>
    <arm_group_label>X-396 (ensartinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>oral ALK inhibitor</description>
    <arm_group_label>crizotinib</arm_group_label>
    <other_name>Xalkori</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage
             IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is
             ALK-positive. Enrollment will be allowed based on positive Abbott FISH or Ventana IHC,
             performed locally or centrally. Patients may have received up to 1 prior chemotherapy
             regimen for metastatic disease, which may also include maintenance therapy. Note that
             patients that have received adjuvant or neoadjuvant chemotherapy and developed
             metastatic disease within 6 months from the end of that therapy would be considered to
             have received 1 prior regimen for metastatic disease.

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.

          3. Life expectancy of at least 12 weeks.

          4. Ability to swallow and retain oral medication.

          5. Adequate organ system function, defined as follows:

               1. Absolute neutrophil count (ANC) ≥1.5 x 109/L

               2. Platelets ≥100 x 109/L

               3. Hemoglobin ≥9 g/dL (≥90 g/L) Note that transfusions are allowed to meet the
                  required hemoglobin level

               4. Total bilirubin ≤1.5 times the upper limit of normal (ULN)

               5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

                  ≤2.5 x ULN if no liver involvement or ≤5 x ULN with liver involvement.

               6. Creatinine ≤1.5 x ULN. If &gt;1.5 x ULN, patient may still be eligible if calculated
                  creatinine clearance ≥50 mL/min (0.83 mL/s) as calculated by the Cockcroft-Gault
                  method.

          6. Brain metastases allowed if asymptomatic at study baseline. Patients with untreated
             brain metastases must not be on corticosteroids. If patients have neurological
             symptoms or signs due to CNS metastases, patients need to complete whole brain
             radiation or focal treatment at least 14 days before start of study treatment and be
             asymptomatic on stable or decreasing doses of corticosteroids at baseline.

          7. Men with partners of childbearing potential willing to use adequate contraceptive
             measures during the study and for 90 days after the last dose of study medication.

          8. Women who are not of child-bearing potential, and women of child-bearing potential who
             agree to use adequate contraceptive measures during the study and for 90 days after
             the last dose of study medication, and who have a negative serum or urine pregnancy
             test within 1 week prior to initial trial treatment.

          9. Patients must be ≥18 years of age.

         10. Patients must have measurable disease per RECIST v. 1.1.

         11. Willingness and ability to comply with the trial and follow-up procedures.

         12. Ability to understand the nature of this trial and give written informed consent.

             Note the following pertains to patients enrolled in France

         13. In France, a subject will be eligible for inclusion in this study only affiliated to
             the French Social Security system, and currently benefit from the corresponding rights
             and cover.

        Exclusion Criteria:

          1. Patients that have previously received an ALK TKI or PD-1/PD-L1 therapy, and patients
             currently receiving cancer therapy (i.e., other targeted therapies, chemotherapy,
             radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or
             tumor embolization).

          2. Use of an investigational drug within 21 days prior to the first dose of study drug.
             Note that to be eligible, any drug-related toxicity should have recovered to Grade 1
             or less, with the exception of alopecia.

          3. Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14
             days.

          4. Patients with primary CNS tumors and leptomeningeal disease are ineligible.

          5. Patients with a previous malignancy within the past 3 years (other than curatively
             treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any
             cancer that is considered to be cured and have no impact on PFS and OS for the current
             NSCLC).

          6. Concomitant systemic use of anticancer herbal medications. These should be stopped
             prior to study entry.

          7. Patients receiving

               1. strong CYP3A inhibitors (including, but not limited to, atazanavir,
                  clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,
                  ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit,
                  grapefruit juice)

               2. strong CYP3A inducers (including, but not limited to, carbamazepine,
                  phenobarbital, phenytoin, rifabutin, rifampin, St. John's Wort)

               3. CYP3A substrates with narrow therapeutic window (including, but not limited to,
                  alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,
                  quinidine, sirolimus, tacrolimus).

          8. Women who are pregnant or breastfeeding.

          9. Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             study medications.

         10. Patients at risk for GI perforation.

         11. Clinically significant cardiovascular disease including:

               1. QTcF interval &gt;450 ms for men and &gt;470 ms for women, symptomatic bradycardia &lt;45
                  beats per minute or other significant ECG abnormalities in the investigator's
                  opinion.

               2. Clinically uncontrolled hypertension in the investigator's opinion (e.g., blood
                  pressure &gt;160/100 mmHg; note that isolated elevated readings considered to not be
                  indicative of uncontrolled hypertension are allowed).

             The following within 6 months prior to Cycle 1 Day 1:

               1. Congestive heart failure (New York Heart Class III or IV).

               2. Arrhythmia or conduction abnormality requiring medication. Note: patients with
                  atrial fibrillation/flutter controlled by medication and arrhythmias controlled
                  by pacemakers are eligible.

               3. Severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial
                  infarction.

               4. Cerebrovascular accident or transient ischemia.

         12. Patients who are immunosuppressed (including known HIV infection), have a serious
             active infection at the time of treatment, have interstitial lung disease/pneumonitis,
             or have any serious underlying medical condition that would impair the ability of the
             patient to receive protocol treatment. Patients with controlled hepatitis C, in the
             investigator's opinion, are allowed. Patients with known hepatitis B must be HBeAg and
             HB viral DNA negative for enrollment. Note that, because of the high prevalence, all
             patients in the Asia-Pacific region (except Australia, New Zealand, and Japan) must be
             tested and, if HBsAg positive, must be HBeAg and HB viral DNA negative for enrollment.

         13. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

         14. Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol or would impart excessive risk associated with study participation
             that would make it inappropriate for the patient to be enrolled.

         15. Inability or unwillingness to comply with study and/or follow-up procedures outlined
             in the protocol.

             Note the following pertains to patients enrolled in France

         16. In France, a subject will not be eligible when under legal protection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jolee D. Holt, RN</last_name>
    <phone>918-899-1012</phone>
    <email>jholt@optimalsites.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Holly Hoefer, MSHC</last_name>
    <phone>918-899-1012</phone>
    <email>optimalcommunity@optimalsites.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milijana Ugrenovic-Petrovic</last_name>
      <phone>813-745-2010</phone>
      <email>milijana.ugrenovic@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Chiappori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>279</phone_ext>
      <email>jhodgson@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros G. Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Alphonsus Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina K. Schied, RN</last_name>
      <phone>208-367-3481</phone>
      <email>Tina.schied@saintalphonsus.org</email>
    </contact>
    <investigator>
      <last_name>Kerry Pulver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
      <phone>313-916-1784</phone>
      <email>tpearce1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Igor Rybkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian McGowan</last_name>
      <phone>314-747-7569</phone>
      <email>irmcgowan@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Saiama Waqar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology-Oncology Associates, PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chu, MD</last_name>
      <phone>631-751-3000</phone>
      <email>dchu@nycancer.com</email>
    </contact>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Fisher</last_name>
      <phone>503-215-2613</phone>
      <email>Brenda.fisher@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel E. Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Combs</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Leora Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Banks</last_name>
      <phone>703-970-6553</phone>
      <email>Stacey.banks@inova.org</email>
    </contact>
    <investigator>
      <last_name>Joan H. Schiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer System</name>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <zip>98503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deidre Dillon, RN</last_name>
      <phone>360-754-3934</phone>
    </contact>
    <investigator>
      <last_name>Xingwei D. Sui, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Clinical Science Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dillon Flynn</last_name>
      <phone>608-262-3865</phone>
      <email>dflynn2@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Ticiana Leal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEMIC</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stella Maris Zarza</last_name>
      <phone>541152990100</phone>
      <phone_ext>2880</phone_ext>
      <email>szarza@cemic.edu.ar</email>
    </contact>
    <investigator>
      <last_name>Gonzalo Recondo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Favaloro</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesica Fontela</last_name>
      <phone>+54-114-3781200</phone>
      <phone_ext>1701</phone_ext>
      <email>yfontela@ffavaloro.org</email>
    </contact>
    <investigator>
      <last_name>Juan Cundom, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Pergamino SA</name>
      <address>
        <city>Pergamino</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Abud</last_name>
      <phone>54 2477445255</phone>
      <email>franciscoabud.cip@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Susana Kahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque S.A.</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Arias</last_name>
      <phone>54 9 341 5067749</phone>
      <email>luarias77@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gaston Martinengo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology Research Unit</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqui McBurnie</last_name>
      <phone>612 6064 1508</phone>
      <email>jmcburnie@bordermedonc.com.au</email>
    </contact>
    <investigator>
      <last_name>Craig Underhill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Dewaele</last_name>
      <phone>024775459</phone>
      <email>alex.dewaele@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lore Decoster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Collet</last_name>
      <phone>32 81423028</phone>
      <email>emilie.collet@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Sebahat Ocak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Paulino, RN</last_name>
      <phone>780-432-8359</phone>
      <email>jennifer.paulino@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Anil Joy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infirmière recherche Clinique, IUCPQ</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Fortin</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2639</phone_ext>
      <email>brigitte.fortin@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Lise Tremblay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjuan Huang</last_name>
      <email>ahhfhwj@163.com</email>
    </contact>
    <investigator>
      <last_name>Lejie Cao, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Zhao</last_name>
      <email>zhaojing.scarlett@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuhui Zhang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhihong Mei</last_name>
      <email>meizhihong@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuankai Shi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoxia Cui</last_name>
      <email>cuixiaoxia8462@163.com</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Yin</last_name>
      <email>yixi9999@126.com</email>
    </contact>
    <investigator>
      <last_name>Ziping Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieran Long</last_name>
      <email>248016800@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jian Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gao Shuhong</last_name>
      <email>gaosh05@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhe Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shujun Yin</last_name>
      <email>66803180@qq.com</email>
    </contact>
    <investigator>
      <last_name>Cheng Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sufen Luo</last_name>
      <email>luosufen07@126.com</email>
    </contact>
    <investigator>
      <last_name>Jinji Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Jin</last_name>
      <email>664874820@qq.com</email>
    </contact>
    <investigator>
      <last_name>Cuimin Ding, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiwei Zhang</last_name>
      <email>zhangweiweiJN@sina.com</email>
    </contact>
    <investigator>
      <last_name>Gongyan Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingqin Wang</last_name>
      <email>wangmingqin1979@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhiyong Ma, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Tongji Medical College of Huazhong Science and Techology University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>420104</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shishi Cheng</last_name>
      <email>skylershishi@126.com</email>
    </contact>
    <investigator>
      <last_name>Gang Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Liu</last_name>
      <email>gcpliumei@163.com</email>
    </contact>
    <investigator>
      <last_name>Shiying Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangfang Fu</last_name>
      <email>273027192@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yanping Hu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Yang</last_name>
      <email>32875997@qq.com</email>
    </contact>
    <investigator>
      <last_name>Nong Yang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bingrong Zhao</last_name>
      <email>zbrspring@126.com</email>
    </contact>
    <investigator>
      <last_name>Chengping Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyan Zhang</last_name>
      <email>zhangjianya_zjy@126.com</email>
    </contact>
    <investigator>
      <last_name>Yong Song, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiong Qiang</last_name>
      <email>1985056904@qq.com</email>
    </contact>
    <investigator>
      <last_name>Anwen Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yongmin</last_name>
    </contact>
    <investigator>
      <last_name>Jiuwei Cui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinmiao Wang</last_name>
      <email>wangxinmiao122@163.com</email>
    </contact>
    <investigator>
      <last_name>Ying Cheng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shujie Jiang</last_name>
      <email>jiangsj6502@126.com</email>
    </contact>
    <investigator>
      <last_name>Yunpeng Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoli Shi</last_name>
      <email>18661628@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhuang Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaojie Tao</last_name>
      <email>13162678531@163.com</email>
    </contact>
    <investigator>
      <last_name>Liyan Jiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Li</last_name>
      <email>tracy.li_2010@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yongmei Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital Mailing No.154 Anshan Avenue Heping District</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Li</last_name>
      <email>fairy624@163.com</email>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Xiaohong</last_name>
      <email>yexiaohpng526739@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yiping Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Yu</last_name>
      <email>jmq313309@163.com</email>
    </contact>
    <investigator>
      <last_name>Yun Fan, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Yin</last_name>
      <phone>+8613301212676</phone>
      <email>yixi9999@126.com</email>
    </contact>
    <investigator>
      <last_name>Ziping Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieran Long</last_name>
      <phone>+8613701224460</phone>
      <email>248016800@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jian Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vítkovická Nemocnice , a.s.</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <zip>70384</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaromir Roubec, MD</last_name>
      <phone>420 565 633 400</phone>
      <email>jaromir.roubec@vtn.agel.cz</email>
    </contact>
    <investigator>
      <last_name>Jaromir Roubec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Pleši s.r.o.</name>
      <address>
        <city>Plesice</city>
        <zip>26204</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Vydra, MD</last_name>
      <phone>420318541502</phone>
      <email>vydra@naplesi.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Vydra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajská zdravotní, a.s., Masarykova nemocnice</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Doležal</last_name>
      <phone>420477113488</phone>
      <email>daniel.dolezal@kzcr.eu</email>
    </contact>
    <investigator>
      <last_name>Pavel Reiterer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Morvan CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Robinet</last_name>
      <phone>02 98 22 33 95</phone>
      <email>gilles.robinet@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Renaudd Descourt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre GF Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anais Grilo</last_name>
      <phone>03 80 73 77 56</phone>
      <email>agrilo@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Coudert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Wasielewski</last_name>
      <phone>333.20.44.59.62</phone>
      <phone_ext>31105</phone_ext>
      <email>eric.wasielewski@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis Cortot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Gestin-Boyer, PhD</last_name>
      <phone>04.67.61.25.08</phone>
      <email>Christine.Gestin-Boyer@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Quantin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Vallée</last_name>
      <phone>+331 42 38 51 10</phone>
      <email>emilie.vallee-willien@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Doucet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Pringent</last_name>
      <phone>33 2 99 28 97 95</phone>
    </contact>
    <investigator>
      <last_name>Hervé Lena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest (ICO)</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Labarre</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <email>lucie.labarre@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine Hiret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hospital Civil de Stasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koukeb Malki-Rouguieg, PhD</last_name>
      <phone>03 69 55 16 75</phone>
      <email>koukeb.malki-rouguieg@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Quiox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik m. S. Infektiologie &amp; Pneumologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Föllmer</last_name>
      <phone>+49-30-450 553 044</phone>
      <email>ulrike.foellmer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Nikolaj Frost, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>D-12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike De Wit, MD</last_name>
      <phone>+49 30130142251</phone>
      <email>maike.dewit@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Maike De Wit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lungen Clinic Grosshansdorf</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Reck, MD</last_name>
      <phone>0049 4102 601 2100</phone>
      <email>m.reck@lungenclinic.de</email>
    </contact>
    <investigator>
      <last_name>Martin Reck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH Med. Klinik II Onkologie</name>
      <address>
        <city>Lowenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Fischer, MD</last_name>
      <phone>49(0)713015 6226</phone>
      <email>juergen.fischer@klinik-loewenstein.de</email>
    </contact>
    <investigator>
      <last_name>Jurgen Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Hämatologie und Onkologie Stolberg</name>
      <address>
        <city>Stolberg</city>
        <zip>D-52222</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Groschek, M</last_name>
      <phone>+49 24027668829</phone>
      <email>praxis@onkologie-stolberg.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Groschek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Kit Man Lee</last_name>
      <phone>85235062641</phone>
      <email>lkm023@ha.org.hk</email>
    </contact>
    <investigator>
      <last_name>Yu Chung Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong/Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Li</last_name>
      <phone>85222554349</phone>
      <email>livivian@hku.hk</email>
    </contact>
    <investigator>
      <last_name>James Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong/Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Chan</last_name>
      <phone>85222555124</phone>
      <email>kskchan@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Victor Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Chak</last_name>
      <phone>85235051202</phone>
      <email>karen@clo.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Tony Mok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Centre</name>
      <address>
        <city>Be'er Sheva`</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilona Hanukov</last_name>
      <phone>97286244127</phone>
      <email>IlonaH@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Julia Dudnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus/ Oncology Institute</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tirza</last_name>
      <phone>972-4-7776750</phone>
      <email>T_DAVID@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Mirjana Wollner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arfa Gilad</last_name>
      <phone>972 2 6776760</phone>
      <email>gilada@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Hovav Nechushtan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Institute of Oncology, Davidoff Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Bromberg</last_name>
      <phone>972 39378086</phone>
      <email>danabr1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Dudnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Onn, MD</last_name>
      <phone>03-5308420</phone>
      <email>Amir.Onn@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Amir Onn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico CRO Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Da Ros</last_name>
      <phone>+39 0434 659079</phone>
      <email>vdaros@cro.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Bearz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Pigozzi</last_name>
      <phone>+390442622801</phone>
      <email>oncologia.medica.leg@aulsslegnago.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Ragazzini, MD</last_name>
      <phone>+39 0543 739268</phone>
      <email>angela.ragazzini@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Boselli</last_name>
      <phone>39 02 94372730</phone>
      <email>sabrina.boselli@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Filippo de Marinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Federico II, Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Bianco</last_name>
      <phone>0039-081-7462061</phone>
      <email>roberto.bianco@unina.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Bianco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Operativo Studi Clinici S.C.Oncologia Medica</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Matocci</last_name>
      <phone>+39 0755784099</phone>
      <email>roberta.matocci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giulio Metro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Dazzi, MD</last_name>
      <phone>+39 0544285778</phone>
      <email>claudio.dazzi@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Dazzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas IRCCS</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Toschi</last_name>
      <phone>+39 02 8224 5945</phone>
      <email>luca.toschi@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Luca Toschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale (ASST) della Valtellina e dell'Alto Laria</name>
      <address>
        <city>Sondrio</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Menatti</last_name>
      <phone>+39 0342521167</phone>
      <email>elisabetta.menatti@asst-val.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Bertolini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Wan Kim, MD, PhD</last_name>
      <email>kimdw@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Wan Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae Ho Lee, MD, PhD</last_name>
      <email>leedaeho@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Dae Ho Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline deBruin</last_name>
      <phone>31 204441621</phone>
    </contact>
    <investigator>
      <last_name>Sayed Hashemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre (MUMC)</name>
      <address>
        <city>Maastricht</city>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carola Schurink</last_name>
      <phone>+31 43-3871049</phone>
      <email>trials.longoncologie@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>AMC Dingemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Ricardo Palma</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaida Cepeda</last_name>
      <phone>511991892324</phone>
      <email>zaidacepeda@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Leiva Galvez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Kukowska</last_name>
      <phone>+48 58 349 22 14</phone>
      <email>kukowska@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Rafal Dziadziuszko, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. M. Sklodowskiej Curie</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Falgowska</last_name>
      <phone>'+48 22 546 30 66</phone>
      <email>malgorzata.falgowska@coi.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Kowalski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution Russian Oncological Scientific Center named after N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yana Chukova</last_name>
      <phone>+79250497216</phone>
      <email>yancha86@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Valeriy Braeder, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Vitamed&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Basmanova</last_name>
      <phone>+7 916 079 39 87</phone>
      <email>0793987@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Poddubskaya, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of the city of Moscow &quot;MOSCOW CITY ONCOLOGY HOSPITAL # 62&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krasnolutskaya Lyubov</last_name>
      <email>protocol-62@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Daniil Stroyakovskiy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BHI of Omsk region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bogdalova</last_name>
      <phone>+79620336776</phone>
      <email>asbogdalova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dvorkin Mikhail, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pavlov First Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Odintsova</last_name>
      <phone>+7 921 787 51 46</phone>
    </contact>
    <contact_backup>
      <last_name>Antonina Cheremnikh</last_name>
      <phone>+7 905 229 12 89</phone>
    </contact_backup>
    <investigator>
      <last_name>Sergei Orlov, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FBI &quot;Scientific Research Institute of Oncology n. a. N. N. Petrov&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasia Boyko</last_name>
      <phone>+7 (812) 596-89-05</phone>
      <email>boyko.anastasija@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Poltoratsky Artem, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Egaña</last_name>
      <phone>0034 948 296696</phone>
      <email>megana@unav.es</email>
    </contact>
    <investigator>
      <last_name>Jose Lopez-Picazo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inés López</last_name>
      <phone>924218040</phone>
      <email>ineslopez.tic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Taus, MD</last_name>
      <phone>34932483137</phone>
      <email>ataus@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Alvaro Taus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laia Lavernia Rosell</last_name>
      <phone>+34 93 553 72</phone>
      <email>llavernia@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Margarita Majem Tarruella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Alonso</last_name>
      <phone>34 935460135</phone>
      <email>talonso@oncorosell.com</email>
    </contact>
    <investigator>
      <last_name>Santiago Viteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Beltrán</last_name>
      <phone>34 93 489 4374</phone>
      <email>mbeltran@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli'</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Garcia Ruiz</last_name>
      <phone>+34 93 724 00 84</phone>
      <email>jgarciar@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Yolanda Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Martin</last_name>
      <phone>+34 972 22 58 28</phone>
      <phone_ext>4028</phone_ext>
      <email>bmartin@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Joaquim Bosch-Barrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Penasco</last_name>
      <phone>+34 91 426 93 93</phone>
      <email>sandraflorez.hgugm@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Calles, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Ltatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Ayuga</last_name>
      <phone>+34 871 202 000</phone>
      <phone_ext>1629</phone_ext>
      <email>sayuga@hsll.es</email>
    </contact>
    <investigator>
      <last_name>Pilar Mut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trakya University Balkan Oncology Hospital</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tugce Banbal</last_name>
      <phone>90 530 108 43 14</phone>
      <email>tugce.banbal@atlascro.com.tr</email>
    </contact>
    <investigator>
      <last_name>Irfan Cicin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengisu Gokkaya</last_name>
      <phone>90 549 610 12 83</phone>
      <email>bengisu.gokkaya@medex-smo.com</email>
    </contact>
    <investigator>
      <last_name>Mustafa Ozguroglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sefika Aksoy</last_name>
      <phone>90 532 355 90 33</phone>
      <email>sefikaaksoy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tuncay Goksel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackwood</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Gratix</last_name>
      <phone>01253 953744</phone>
      <email>karen.gratrix@bfwhospitals.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sin Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Morley</last_name>
      <phone>+44 (0)117 414 8114</phone>
      <email>anna.morley@nbt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Alfredo Addeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings Mill hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Smith</last_name>
      <phone>01623 672 440</phone>
      <email>susan.smith1@sfh-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ivo Hennig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Rose</last_name>
      <phone>0151 556-5423</phone>
      <email>sarah.rose@clatterbridgecc.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Carles Escriu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK-positive NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

